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Abstract 
Background: The immunological literature has been redefining clinical phenomena as hypotheses emerge regard-
ing causal links between triggers, immunologic manifestations, and their specific inflammatory cascades. Of late, 
autoimmune manifestations that appear to be caused by an external adjuvant have been grouped into a complex 
syndrome referred to as autoimmune/inflammatory syndrome induced by adjuvants (ASIA). This syndrome may 
present with diverse clinical problems, which may include neurocognitive impairment, inflammatory musculoskeletal 
changes, and constitutional symptoms. There is evidence in the literature linking vaccines to different auto-immune 
manifestations. Vaccines have not traditionally been reported to trigger ASIA, although reports are emerging linking 
the human papilloma virus and hepatitis B vaccines to it.
Case presentation: We report the first suspected case of ASIA in a previously healthy patient who received the Fluad 
seasonal influenza vaccine, which contains the MF59 adjuvant. He presented to hospital with profound weakness 
and was diagnosed with severe rhabdomyolysis. He also had elevated troponin-I and extensive cardiac investigations 
enabled the diagnosis of myocarditis. His infectious and rheumatologic work-ups were negative. He responded well 
to conservative management and did not require immune suppressive therapy.
Conclusion: Given the benefits of the influenza vaccine, and the low incidence of clinically significant complications, 
we encourage ongoing seasonal influenza immunization. However, ongoing surveillance is required to evaluate the 
occurrence of rare adverse events, including ASIA.
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Background
Adjuvants are elements that induce an inflammatory 
response. In the case of vaccines, adjuvants increase 
the antigen-specific immune response, to ultimately 
improve vaccine immunogenicity. This process may 
also have negative repercussions, inducing autoimmun-
ity. Since 2011, autoimmune manifestations that appear 
to be caused by an external adjuvant have been grouped 
into a complex entity referred to as autoimmune/
inflammatory syndrome induced by adjuvants (ASIA) 
[1, 2]. Previously referred to as Shoenfeld’s syndrome, 
the disorder has been redefined; it is characterized by 
neurocognitive, inflammatory musculoskeletal, and/
or constitutional symptoms upon exposure to an exter-
nal stimulus, improvement following withdrawal of the 
offending agent, and may involve the development of 
autoantibodies, specific HLA phenotypes or evolution 
into a rheumatological disorder [3]. The exact mecha-
nisms linking external adjuvants to the various immune 
responses described are not known.
There is longstanding literature linking vaccines to dif-
ferent auto-immune manifestations [4]. In recent years, 
immunizations [5–7], especially the human papilloma 
virus and hepatitis B virus vaccines [8], and various vac-
cine adjuvants [9, 10] have been linked to ASIA. However, 
the seasonal influenza vaccine is an uncommon trigger 
for autoimmune disease, and is not commonly associated 
with rhabdomyolysis or myocarditis. One study showed 
a tendency for autoantibody production in adults fol-
lowing the influenza vaccine, but without clinical disease 
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correlation [11]. We report the first suspected case of a 
seasonal influenza vaccine induced-ASIA in a previously 
healthy male who presented to hospital with simultane-
ous rhabdomyolysis and myocarditis.
Case presentation
A 65 year old previously healthy male presented to hospi-
tal with profound weakness. Five days before admission, 
he had received the Fluad seasonal influenza vaccine, 
comprised of one influenza A H1/N1 virus, one influ-
enza A H3/N2 virus, one influenza B virus, and the MF59 
adjuvant. Two days later, he developed bilateral crampy 
leg pain, muscle tenderness, and progressive weakness. 
He became unable to weight-bear and was brought to 
the emergency department by his wife. He denied expe-
riencing headaches, paresthesias, arthralgias, skin lesions 
or constitutional symptoms. An infectious review of sys-
tems was unremarkable. He was not taking any medica-
tions or herbal preparations prior to admission, nor did 
he use recreational drugs.
On physical exam his vital signs were: pulse 92/min-
ute, blood pressure 124/84, respiratory rate 20/minute, 
oral temperature 36.7  °C, and his oxygen saturation was 
100  % on room air. His neurological exam was signifi-
cant for 4/5 strength in bilateral hip flexors, hip exten-
sors, hip abductors and hip adductors. He could not 
stand from the sitting position without the aid of his 
arms. The large muscle groups of his arms and legs were 
tender. Cardiac examination revealed a jugular venous 
pressure (JVP) two cm above the sternal angle, a normal 
apical beat, a normal S1 and S2 without any extra heart 
sounds, murmurs or rubs. His respiratory exam revealed 
mild crackles in the left lower lobe. The remainder of the 
examination was unremarkable.
His blood counts were WBC 11  ×  99/L, hemo-
globin 123  g/L (MCV 83  fL) and platelets 134 ×  109/L. 
Electrolytes included sodium 126  mmol/L, potas-
sium 3.2  mmol/L, chloride 101  mmol/L, bicarbonate 
17  mmol/L, phosphate 0.75  mmol/L and magnesium 
0.97 mmol/L. Other laboratory parameters included urea 
11.6  mM/L, creatinine 157  mM/L, creatine kinase (CK) 
7736 U/L (normal < 150 U/L) and troponin-I 9.44 mcg/L 
(normal < 0.2 mcg/L). A blood ethanol level was negative. 
His EKG revealed normal sinus rhythm and a right bun-
dle branch block, without ischemic features. A chest radi-
ograph and contrast enhanced computed tomography 
scan of the chest revealed a hiatus hernia, left lower lobe 
opacification, without evidence of pulmonary embolism.
Acute rhabdomyolysis was diagnosed and the patient 
received four liters of fluid over the ensuing 24  h. Dur-
ing volume resuscitation, he developed pulmonary crack-
les, his JVP increased to 5  cm above the sternal angle, 
and his oxygen saturation decreased to 90 % on room air. 
Supplemental oxygen and a single dose of furosemide 
40 mg IV were provided, to which he responded well. He 
also initially received piperacillin–tazobactam for pos-
sible left lower lobe pneumonia. No steroids were pre-
scribed. His creatinine, CK and troponin levels trended 
downwards after 12 h of therapy, and almost normalized 
within 5 days (see Fig. 1).
A basic immunological workup was within normal 
limits, with an antinuclear antibody test (ANA) of 1:160, 
homogeneous pattern (non-specific), and negative anti-
dsDNA, ENA panel, C3, C4, rheumatoid factor, and 
ANCA tests. Serum protein electrophoresis (SPEP) was 
consistent with an acute phase reaction and urine protein 
electrophoresis (UPEP) was negative. Dipstick urinalysis 
revealed 1+ protein and 1+ blood and his urine was pos-
itive for myoglobin. Microscopy revealed granular casts, 
urate crystals and no evidence of red blood cells. HIV, 
hepatitis B and C serological tests were negative. Blood 
and urine cultures yielded no growth. Computed tomog-
raphy scans of the head and lumbar spine were negative; 
no other cause was found to explain the patient’s weak-
ness. An echocardiogram performed on day three of 
admission revealed normal biventricular systolic func-
tion without regional wall motion abnormalities. Cardiac 
MRI on day four confirmed the diagnosis of myocarditis. 
A muscle biopsy was not performed as the patient recov-
ered promptly; he was discharged home on day six.
Discussion
This patient presented with a gradual onset of weakness 
and muscular pain. He had received the influenza vac-
cine 5  days prior to the onset of symptoms. Laboratory 
investigations indicated rhabdomyolysis, myocarditis, 
and acute kidney injury, which all resolved by the sixth 
day of admission.
In rhabdomyolysis, there is breakdown of skeletal mus-
cle cells, resulting in the release of cellular constituents 
such as electrolytes, myoglobin and cellular enzymes, 
including creatine kinase. The consequences thereof can 
include life threatening disseminated intravascular coag-
ulation, electrolyte disturbances, and acute kidney injury. 
There are numerous known causes of rhabdomyolysis 
[12, 13]; they are summarized in Table 1.
Aggressive fluid management is key in avoiding myo-
globin-induced oxidative damage to the kidney [13]. This 
patient was treated with modest fluid resuscitation, due 
to the concern of circulatory overload in the context 
of suspected cardiac myositis. He did indeed develop 
signs of volume overload (increased JVP and respira-
tory crackles), with favorable response to decreased fluid 
administration and a diuretic. In addition to the nephro-
toxic effects of myoglobin, recent evidence suggests that 
pro-inflammatory cytokines, chemokines and NLRP3 
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inflammasomes partake in the pathogenesis of rhabdo-
myolysis-induced acute kidney injury [14], highlighting 
the importance for additional research in the manage-
ment of this condition.
As the history, physical examination, and laboratory 
markers did not suggest an alternative cause for rhab-
domyolysis, we believe that his presentation was most 
in keeping with ASIA. Furthermore, he fulfilled many 
of the major suggested criteria for the diagnosis of ASIA 
(see Table 2). Connective tissue causes of myositis were 
ruled out by the normal ANA titer, and negative ENA, 
C3, C4, RA, and ANCA panels. Illness resolution without 
anti-inflammatory or immunomodulatory medication 
also goes against connective tissue diseases. The physical 
examination, SPEP, UPEP, and CT scans were not sugges-
tive of Guillain–Barré syndrome. His cardiac evaluation 
suggested myocarditis and not myocardial infarction as 
a cause for the troponinemia. Unfortunately, while the 
patient’s blood cultures were negative, the patient did not 
produce any sputum for culture, and a respiratory poly-
merase chain reaction (PCR) panel to detect common 
respiratory pathogens was not obtained. Although infec-
tious etiologies of rhabdomyolosis have been previously 
well described [15–18], we suspect these to be less likely, 
Fig. 1 Trend of patient’s creatine kinase and troponin-I
Table 1 Common causes of rhabdomyolysis
Category Example
Autoimmune diseases Dermatomyositis and polymyositis
Drugs and toxins Numerous: including alcohol, cocaine, heroin, fibrates and statins
Electrolyte disorders Hypokalemia, hypernatremia, hyponatremia, hypophosphatemia, hypocalcemia, hyperosmolarity, ketoacidosis
Endocrine disorders Hypothyroidism, hyperaldosteronism
Excessive muscle activity Alcohol withdrawal, exercise, seizures
Genetic disorders Numerous: including disorders of glycolysis, glycogenolysis, lipid metabolism, mitochondrial pathways and nucleotide 
metabolism
Hypoxia Prolonged immobilization, artery occlusion
Idiopathic
 Infections Viral (coxsackievirus, Epstein–Barr virus, herpes viruses, HIV, influenza A and B) 
Bacterial (Clostridium spp., F. tularensis, L. pneumophilia, Salmonella spp., S. pyogenes, S. aureus) 
Parasitic (malaria)
 Temperature Heatstroke, malignant hyperthermia, malignant neuroleptic syndrome, hypothermia
 Trauma and compres-
sion
Crush injury syndrome, electrical injury
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as the patient denied upper and lower respiratory tract 
infection symptoms.
Few reports propose an association between the influ-
enza vaccine and rhabdomyolysis and/or myocarditis. 
There are three case reports of rhabdomyolysis follow-
ing influenza immunization. However, unlike our case, 
all three patients were taking a statin drug, and none had 
features of myocarditis. The first two reports describe 
patients on statin therapy who developed myalgia and 
progressive weakness within 24  h of receiving the flu 
vaccine, who were diagnosed with rhabdomyolysis and 
acute kidney injury [19, 20]. The third published case of 
rhabdomyolysis was described 1 week post influenza vac-
cination in a 57 year old renal transplant patient on simv-
astatin and cyclosporin A [21]. A final case was reported 
in the literature: a 60 year old gentleman who developed 
polyarthropathy, orbital myositis and posterior scleri-
tis 10 days after receiving the 1993 Fluvirin vaccine [22]. 
Given the ocular involvement, he received oral predni-
solone and acetazolamide, with dramatic improvement 
over the next four months.
Shoenfeld et  al. [23] suggest grouping different auto-
immune manifestations that are seemingly triggered by 
an external adjuvant into a syndrome complex, referred 
to as autoimmune/inflammatory syndrome induced by 
adjuvants (ASIA). Numerous mechanisms have been 
proposed to explain the interaction between adjuvants, 
immunogenicity, and autoimmunity. Many researchers 
postulate that individuals who develop autoimmune phe-
nomena following vaccination have a genetic risk or an 
underlying disease that activates inappropriate immune 
responses [1, 7, 24, 25]. ASIA is characterized by a myr-
iad of neurocognitive manifestations, including chronic 
fatigue, cognitive impairment and amnesia, as well as 
the development of inflammatory musculoskeletal find-
ings including arthritis and myositis [3]. Our patient’s 
presentation would be more in keeping with the latter 
end of the disease spectrum. He fulfills the original diag-
nostic requirements proposed by Shoenfeld et  al. (see 
Table  2) [23]. Although inflammatory myopathies have 
been well described following vaccination [25], includ-
ing macrophagic myofaciitis (MMF) [26], the occurrence 
of myocarditis has not. Furthermore, our patient did 
not manifest a locally stereotyped or immunologically 
active lesion at the site of inoculation, which would argue 
against MMF. Despite the atypical nature of our patient’s 
presentation, including cardiac involvement, we believe 
that his profound inflammatory response may be attrib-
uted to the recent vaccine in the absence of other causes, 
especially given the timing of adjuvant exposure.
As described in a recent systematic literature review and 
meta-analysis, while local injection site pain and head-
ache are known reactions, serious adverse effects follow-
ing influenza immunization are rare [27]. Though cases 
of myositis have been described in adults after hepatitis 
B or BCG vaccination [28, 29], cases linking the influenza 
vaccine to myositis without confounding factors are rare. 
Although an argument can be made regarding the patient’s 
radiographic opacification as a possible confounder, we are 
not convinced that the patient had an infectious process. 
Based on the patient’s clinical and laboratory findings, a 
presumptive diagnosis of ASIA was made.
As mentioned, there is convincing data in the litera-
ture that the influenza vaccine is safe and effective (27). 
Significant complications are rare. In addition to hand-
hygiene and respiratory etiquette, immunization is an 
Table 2 Criteria suggested ASIA diagnosis
For the diagnosis of ASIA, the presence of at least 2 major or 1 major and 2 minor criteria must be apparent. Table reprinted from Journal of Autoimmunity, vol. 36(1), 
Yehuda Shoenfelda and Nancy Agmon-Levin, ‘ASIA’—Autoimmune/inflammatory syndrome induced by adjuvants, pages 4–8, Copyright 2011, with permission from 
Elsevier
Exposure to an external stimuli (Infection, vaccine, silicone, adjuvant) prior to clinical manifestations
Major criteria  The appearance of ’typical’ clinical manifestations:
    Myalgia, Myositis or muscle weakness
  Arthralgia and/or arthritis
    Chronic fatigue, un-refreshing sleep or sleep disturbances
  Neurological manifestations (especially associated with demyelination)
  Cognitive impairment, memory loss
  Pyrexia, dry mouth
Removal of inciting agent induces improvement
Typical biopsy of involved organs
Minor criteria The appearance of autoantibodies or antibodies directed at the suspected adjuvant
Other clinical manifestations (i.e. irritable bowel syn.)
Specific HLA (i.e. HLA DRB1, HLA DQB1)
Evolvement of an autoimmune disease (i.e. MS, SSc)
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effective tool to curb the spread of the influenza virus 
[30]. Annual vaccination has been shown to protect indi-
viduals of all ages from the flu, decreasing rates of emer-
gency room visits, hospitalization, and death [31]. These 
benefits outweigh the mild adverse effects, prompting 
many countries to continue wide-reaching annual influ-
enza vaccination campaigns [32].
Conclusion
We report the case of a 65-year-old previously healthy 
male who presented to hospital with acute rhabdomy-
olysis and myocarditis 5 days after the administration of 
a seasonal influenza vaccine. This may have been due to 
the adjuvant in the vaccine, although alternate etiolo-
gies cannot be eliminated. At this time, the incidence of 
rhabdomyolysis and myocarditis post vaccination is lim-
ited to case reports. ASIA is an emerging clinical entity, 
with its share of case reports hypothesizing a causal link 
with vaccines. Given the benefits of the influenza vaccine, 
especially in the health care setting and in many vulner-
able populations, compared to the rarity of this and other 
putative complications, we encourage ongoing seasonal 
influenza immunization campaigns. Furthermore, most 
available seasonal flu vaccines do not contain any adju-
vants. Ongoing surveillance to establish the existence 
of this posited entity and to evaluate its risks should be 
pursued.
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